提示: 手机请竖屏浏览!

Hormone Therapy for Postmenopausal Women

JoAnn V. Pinkerton ... 妇产科和儿科 • 2020.01.30
• 北美绝经期学会更新关于激素疗法的立场声明:2017 • 更多证据支持激素疗法的时机假说 • 绝经期激素疗法与静脉血栓栓塞风险:给药途径很重要 • 雌激素-孕激素疗法增加乳腺癌风险——这是否会影响临床实践



JoAnn V. Pinkerton, M.D.
From the University of Virginia Health System, Charlottesville. Address reprint requests to Dr. Pinkerton at the University of Virginia Health System, Box 8041014, Charlottesville, VA 22908-1104, or at jvp9u@virginia.edu.



1. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol 2014;142:115-120.

2. Gibson CJ, Huang AJ, McCaw B, Subak LL, Thom DH, Van Den Eeden SK. Associations of intimate partner violence, sexual assault, and posttraumatic stress disorder with menopause symptoms among midlife and older women. JAMA Intern Med 2019;179:80-87.

3. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531-539.

4. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017;24:728-753.

5. Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric 2018;21:96-100.

6. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause 2014;21:1063-1068.

7. Manson JE, Kaunitz AM. Menopause management — getting clinical care back on track. N Engl J Med 2016;374:803-806.

8. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol 2017;13:220-231.

9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.

10. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-631.

11. Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms. Obstet Gynecol 2015;126:413-422.

12. Kaunitz AM. Extended duration use of menopausal hormone therapy. Menopause 2014;21:679-681.

13. Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med 2019;24:2515690X19829380-2515690X19829380.

14. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978-CD002978.

15. Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause 2017;24:238-246.

16. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.

17. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.

18. Canonico M, Scarabin PY. Oral versus transdermal estrogens and venous thromboembolism in postmenopausal women: what is new since 2003? Menopause 2016;23:587-588.

19. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364:k4810-k4810.

20. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159-1168.

21. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 2014;142:83-89.

22. Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and Alzheimer disease: a prospective cohort study. Neurology 2017;88:1062-1068.

23. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291:2947-2958.

24. Espeland MA, Rapp SR, Manson JE, et al. Long-term effects on cognitive trajectories of postmenopausal hormone therapy in two age groups. J Gerontol A Biol Sci Med Sci 2017;72:838-845.

25. Lee AW, Ness RB, Roman LD, et al. Association between menopausal estrogen-only therapy and ovarian carcinoma risk. Obstet Gynecol 2016;127:828-836.

26. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA 2017;318:927-938.

27. ACOG practice bulletin no. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202-216.

28. Taylor HS, Tal A, Pal L, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med 2017;177:1471-1479.

29. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111.

30. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189-E198.

31. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118:Suppl 12B:163-165.

32. Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015;18:483-491.

33. Gramling R, Eaton CB, Rothman KJ, Cabral H, Silliman RA, Lash TL. Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology 2009;20:752-756.

34. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975-4011.

35. Marchetti C, De Felice F, Boccia S, et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol 2018;132:111-115.

36. Zeleke BM, Davis SR, Fradkin P, Bell RJ. Vasomotor symptoms and urogenital atrophy in older women: a systematic review. Climacteric 2015;18:112-120.

37. Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric 2019;22:544-552.

38. Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016;315:2554-2563.

39. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058-1066.

40. Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2009;4:CD001405-CD001405.

41. Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 2018;26:603-610.

42. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 2018;25:11-20.

43. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic levels with low-dose vaginal estrogens. Menopause 2019 December 2 (Epub ahead of print).

44. Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab 2017;102:3647-3661.

45. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, Farrell R. ACOG committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016;127(3):e93-e96.

46. Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA. Neurokinin 3 receptor antagonism reveals roles for neurokinin B in the regulation of gonadotropin secretion and hot flashes in postmenopausal women. Neuroendocrinology 2018;106:148-157.

47. Cobin RH, Goodman NF. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause — 2017 update. Endocr Pract 2017;23:869-880.

48. Grossman DC, Curry SJ, Owens DK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. JAMA 2017;318:2224-2233.

49. Reid R, Abramson BL, Blake J, et al. Managing menopause. J Obstet Gynaecol Can 2014;36:830-833.

50. Lumsden MA, Davies M, Sarri G. Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) guideline. JAMA Intern Med 2016;176:1205-1206.

51. Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109-150.

52. de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016;19:313-315.

53. Manson JE, Ames JM, Shapiro M, et al. Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from the North American Menopause Society. Menopause 2015;22:247-253.

服务条款 | 隐私政策 | 联系我们